[ @entity4562 (Iressa) in the treatment of @entity1149 XXXX ].

@entity1 @entity137 @entity4562 @entity1910 @entity470 @entity5 @entity294 @entity1149 @entity2 @entity669
BACKGROUND: To investigate the antitumor effects and @entity137 of @entity470 ( @entity470 )- @entity669 kinase inhibitor @entity4562 (Iressa) in @entity1 with advanced @entity1149 ( @entity1149 ). METHODS: From December 2002 to August 2003, 39 @entity1 with unresectable @entity1149 were enrolled for 250 mg once-daily oral treatment with @entity4562 . Clinical data was analysed using chi-square test, t test and Kaplan-Meier survival analysis. Quality of Life (QoL) was analyzed using Chinese Version of European Organization for Research and Treatment of @entity5 (EORTC) core questionnaire QLQ-C30 and @entity2 related questionnaire QLQ-LC13. RESULTS: @entity5 response rate (complete response and partial response) was 28.2% . Disease control rate, which included both @entity5 responses and stable disease, was 59.0%. Objective @entity5 response was correlated with gender and pathological type. Time to progress was (6.6  1.6) months (95% CI, 3.4-9.7), and 1 year survival rate was 54.3%. Response rate of @entity2 -related symptom scales were 34.8%, 65.2% and 73.9% respectively. The @entity4562 of 250 mg/d was well tolerated by @entity1 . The majority of adverse events were grade I or grade II @entity1910 and @entity294 , which were manageable and reversible. CONCLUSIONS: @entity4562 offers a new treatment option providing meaningful @entity5 control and symptom relief for many @entity1 with advanced @entity1149 .
